Wang et al. [111] investigated the therapeutic potential of the FXR and G protein-coupled receptor 5 (TGR5) axis in the treatment of non-alcoholic steatohepatitis (NASH) [111]. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.